![Biology Faculty Proceedings, Presentations, Speeches, Lectures](../../assets/md5images/2ef20ed3c4966dc98bab77eebdedecca.png)
Biology Faculty Proceedings, Presentations, Speeches, Lectures
Event Name/Location
2020 Experimental Biology Annual Meeting
Presentation Date
4-20-2020
Document Type
Conference Proceeding
ORCID ID
0000-0001-6295-9928
Proceeding Title
The FASEB Journal, Volume 34, Issue S1
ISSN
1530-6860
Description
Human immunodeficiency virus (HIV) affects approximately 37 million people worldwide and results in over 1 million deaths annually. A class of drugs first developed in 1995 inhibits the enzyme HIV‐1 protease, thus preventing the maturation of an HIV precursor protein. There are now over 10 protease inhibitors available to treat HIV. Multiple mutations in the protein have made this treatment less effective. The CREST (Connecting Researchers, Educators, and STudents) team at Nova Southeastern University modeled the interaction between HIV‐1 protease and its competitive inhibitors. Darunavir is currently one of the strongest competitive inhibitors, as it binds effectively to the substrate envelope and has yielded a lower resistance for patients. The most effective treatment is a combination of two of these inhibitors: Darunavir and Ritonavir. In order to explain how these drugs work, the active site of the non‐mutated wild‐type HIV‐1 protease was depicted as a binding box model. The protease inhibitors Darunavir, Ritonavir, and our hypothetical drug, “Sharkavir” were 3D printed to show how they fit into the protease active site. Details of the wild‐type HIV‐1 protease, as well as the drugs Darunavir, and Ritonavir, were found in the Protein Data Bank files, 1T3R, 4DQF, and 1N49, respectively. Both structures were imported into Jmol: a protein visualization software. The new protease inhibitor molecule, “Sharkavir”, was designed as a combination of Darunavir and Ritonavir using Marvin Sketch: a software used to manipulate molecular structures. The molecular structure of the hypothetical drug “Sharkavir” is shown below.
DOI
10.1096/fasebj.2020.34.s1.03303
NSUWorks Citation
Hunt, Matthew; Abbas, Feza; Abbas, Lyla; Ghali, Mina; Ghali, Helana; Chabbra, Alesa; Schmitt Lavin, Emily; and Sikora, Arthur, "Development of "Sharkavir": A Hypothetical Inhibitor for HIV-1 Protease" (2020). Biology Faculty Proceedings, Presentations, Speeches, Lectures. 424.
https://nsuworks.nova.edu/cnso_bio_facpres/424
Additional Comments
NSF-IUSE grant #: 1725940